Results of lung cancer drug’s new trial send Antisoma’s shares soaring - The Times 23rd August 2007

Shares in the biotechnology group Antisoma soared 19 per cent yesterday after the company announced promising results from a clinical trial of an experimental lung cancer medicine. Antisoma said that a new Phase-II study of the drug, known as ASA404, supported earlier findings suggesting that its use in combination with chemotherapy had led to one of the biggest increases in survival reported in the treatment of nonsmall cell lung cancer.

Link to Article